ANGPT2
Angiopoietin-2
As of the edition of 20 October 2026, ANGPT2 (angiopoietin-2, UniProt O15123) has 8 drugs tested at it and 7 companies on the list, 4 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O15123
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 7
- Disease areas
- Cancer; Eye; Urinary and reproductive; Pregnancy and women's health; Hormones; Heart and blood vessels; Skin and connective tissue; Digestive system
- Registered trials of its drugs
- 92
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 3 |
| Stopped | 4 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Faricimab | Marketed | Phase 4 | Ends 2034 |
| Trebananib | Stopped | Phase 3 | none listed |
| Nesvacumab | Went quiet | Phase 2 | none listed |
| CVX-060 | Stopped | Phase 2 | none listed |
| Vanucizumab | Went quiet | Phase 2 | none listed |
| MEDI-3617 | Went quiet | Phase 1 | none listed |
| Zansecimab | Stopped | Phase 2 | none listed |
| AMG-780 | Stopped | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 7 |
The other 4 companies at ANGPT2
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at ANGPT2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.